Education
About Us
Working with TipRanks
Follow Us
Amicus Therapeutics (FOLD)
NASDAQ:FOLD
FOLD Stock Chart & Stats
$14.25
-$0.18(-1.98%)
At close: 4:00 PM EST
$14.25
-$0.18(-1.98%)
Day’s Range― - ―
52-Week Range$5.51 - $14.36
Previous CloseN/A
Volume320.41K
Average Volume (3M)12.59M
Market Cap
$4.41B
Enterprise Value$2.63B
Total Cash (Recent Filing)$263.84M
Total Debt (Recent Filing)$442.82M
Price to Earnings (P/E)―
Beta0.49
Next Earnings
Feb 19, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding309,309,360
10 Day Avg. Volume29,169,311
30 Day Avg. Volume12,586,896
Financial Highlights & Ratios
PEG Ratio0.79
Price to Book (P/B)14.78
Price to Sales (P/S)5.43
P/FCF Ratio-76.57
Enterprise Value/Market Cap0.60
Enterprise Value/Revenue4.38
Enterprise Value/Gross Profit4.90
Enterprise Value/Ebitda44.29
Forecast
1Y Price Target
$14.21Price Target Upside-0.28% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.02
Revenue Forecast (FY)$629.25M
Bulls Say, Bears Say
Bulls Say
Profitability And Financial GrowthAmicus reported strong revenue growth and continued momentum in its core Pompe and Fabry disease franchises, positioning the company for GAAP profitability for 2H25 and projecting over $1B in total revenue by fiscal year 2028.
Revenue GrowthThe deal is anticipated to accelerate revenue growth for Galafold and PomOp due to BMRN's global commercial rare-disease footprint.
Strategic AcquisitionThe acquisition of FOLD by BMRN is expected to create strong synergies due to the compatibility of their rare ERT business.
Bears Say
Analyst DowngradeFollowing the acquisition, the recommendation for FOLD has been downgraded to Neutral/High Risk.
Price Target ReductionThe price target has been lowered from $20.00 to $14.50.
Stock Recommendation DowngradeThe recommendation has been downgraded to Hold, reflecting a more cautious outlook for the stock.
Amicus News
FOLD FAQ
What was Amicus Therapeutics’s price range in the past 12 months?
Amicus Therapeutics lowest stock price was $5.51 and its highest was $14.36 in the past 12 months.
What is Amicus Therapeutics’s market cap?
Amicus Therapeutics’s market cap is $4.41B.
When is Amicus Therapeutics’s upcoming earnings report date?
Amicus Therapeutics’s upcoming earnings report date is Feb 19, 2026 which is in 54 days.
How were Amicus Therapeutics’s earnings last quarter?
Amicus Therapeutics released its earnings results on Nov 04, 2025. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.039 by $0.021.
Is Amicus Therapeutics overvalued?
According to Wall Street analysts Amicus Therapeutics’s price is currently Overvalued.
Does Amicus Therapeutics pay dividends?
Amicus Therapeutics does not currently pay dividends.
What is Amicus Therapeutics’s EPS estimate?
Amicus Therapeutics’s EPS estimate is 0.07.
How many shares outstanding does Amicus Therapeutics have?
Amicus Therapeutics has 309,309,360 shares outstanding.
What happened to Amicus Therapeutics’s price movement after its last earnings report?
Amicus Therapeutics reported an EPS of $0.06 in its last earnings report, beating expectations of $0.039. Following the earnings report the stock price went up 1.467%.
Which hedge fund is a major shareholder of Amicus Therapeutics?
Currently, no hedge funds are holding shares in FOLD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Amicus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$14.21 (-0.28% Downside)
$14.21 (-0.28% Downside)
Blogger Sentiment
Bullish
FOLD Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 467.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.1%
Last 30 Days ▲ 17.2%
Last 30 Days ▲ 17.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
45.55%
12-Months-Change
Fundamentals
Return on Equity
-6.87%
Trailing 12-Months
Asset Growth
10.46%
Trailing 12-Months
Company Description
Amicus Therapeutics
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
FOLD Company Deck
FOLD Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call for Amicus Therapeutics highlights strong financial performance with notable revenue growth and GAAP profitability, driven by their flagship products and global market expansion. Despite some increase in costs and early-stage profitability, the company's strategic focus on expanding their product pipeline and market presence suggests a positive outlook.View all FOLD earnings summariesFOLD Stock 12 Month Forecast
Average Price Target
$14.21
▼(-0.28% Downside)
Technical Analysis
Catalyst Pharma
―
Travere Therapeutics
―
Ocular Therapeutix
―
Immunovant
―
Disc Medicine
―
Ownership Overview
1.15% Insiders
28.07% Mutual Funds
28.26% Other Institutional Investors
22.95% Public Companies and
Individual Investors